Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
Tetracaine hydrochloride is a topical ophthalmic anesthetic solution approved by the FDA in March 2019 for use in eye procedures and examinations. It is a small-molecule local anesthetic that works by blocking sodium channels in nerve cell membranes, preventing pain signal transmission. The drug is administered directly to the eye surface to provide rapid numbing for diagnostic and surgical ophthalmic procedures.
The product is in peak commercial stage with moderate competitive pressure (30% intensity), indicating a stable but competitive market requiring focused commercial execution.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Tetracaine hydrochloride offers limited direct linked job opportunities (0 positions tracked), reflecting its niche position in the ophthalmic anesthetic market. Career growth on this brand depends on commercial execution, market share defense, and supporting Bausch + Lomb's ophthalmology portfolio strategy.
Worked on TETRACAINE HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.